cjc+1295+ipamorelin CJC-1295 / Ipamorelin | Clinician-Reviewed Peptide Therapy CJC-1295 + Ipamorelin Research Peptide

29 in stock Synergistic peptide blend studied for growth hormone release and recovery signaling

This eliminates the fear of excess production often associated with synthetic HGH therapies

Common Model Organisms The CJC-1295 + Ipamorelin blend has been studied across multiple species and experimental systems: Humans Phase I/II clinical trials in healthy volunteers (ages 21-61)

Routes of Administration Subcutaneous injection (standard): Belly fat, thigh, or anywhere with SC tissue

The results suggested that the peptide may be considerably more potent than regular GRF 1-29

This examination may be subject to debate in the face of extremely low central ghrelin levels